| Name | Treosulfan |
| Description | Treosulfan (NSC 39069) is a bifunctional alkylating agent used in the treatment of advanced ovarian cancer.[2] |
| In vitro | METHODS: ES cell lines A4573, CHP-100, JR (NCI-EWS 94), RD-ES, SK-N-MC, TC32, and TC71 were treated with Treosulfan (NSC 39069)(1, 10, 100, 1000 μM), and cell viability was measured by MTT assay.
RESULTS The IC50 values of A4573, CHP-100, JR (NCI-EWS 94), RD-ES, SK-N-MC, TC32, and TC71 were (35, 70, 100, 250, 75, 5, 50, 10 μM). [1] |
| In vivo | METHODS: NOD/SCID mice were injected with ES sarcoma cell line TC71 or CHP-100 in the left gastrocnemius muscle. When tumors were palpable, mice were injected with Treosulfan (NSC 39069) (3,000 mg/kg, i.p), busulfan (60 mg/kg, i.p), or vehicle (PBS/20% DMSO, i.p).
RESULTS Treosulfan significantly inhibited tumor growth in both cell lines, whereas busulfan only caused an initial inhibition of tumor growth in the cell line TC71 and caused tumor growth in mice injected with the cell line CHP-100 on day 13 Moderately suppressed. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (359.32 mM)
H2O : 50 mg/mL (179.66 mM), Sonication is recommended.
|
| Keywords | inhibit | NSC-39069 | DNA Alkylator/Crosslinker | Inhibitor | Treosulfan | NSC39069 |
| Inhibitors Related | Cyclophosphamide hydrate | Bendamustine hydrochloride | Busulfan | N-Nitroso-N-methylurea | Ifosfamide | Oxaliplatin | Streptozocin | Temozolomide | Methyl methanesulfonate | Cyclophosphamide | Carboplatin | Cisplatin |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
